ANTI-CD52 TREATMENT EXPERIENCE IN A T-CELL PROLYMPHOCYTIC LEUKEMIA PATIENT:CASE REPORT

Objective: T-cell prolymphocytic leukemia (T-PLL) is a rare and highly aggressive T cell neoplasm with rapidly progressing clinical course. T-PLL accounts for 2% of mature lymphocytic leukemia in adults. Median overall survival with modern therapy is reported one to three years. Here we report a T-P...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Senem MARAL, Murat ALBAYRAK, Hacer Berna OZTURK, MerihREIS ARAS, Fatma YILMAZ, Pınar TIGLIOGLU, Mesut TIGLIOGLU, Buğra SAGLAM
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/39d3aa3066d64189aaf2033276fee2f5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:39d3aa3066d64189aaf2033276fee2f5
record_format	dspace
spelling	oai:doaj.org-article:39d3aa3066d64189aaf2033276fee2f52021-11-10T04:34:41ZANTI-CD52 TREATMENT EXPERIENCE IN A T-CELL PROLYMPHOCYTIC LEUKEMIA PATIENT:CASE REPORT2531-137910.1016/j.htct.2021.10.1014https://doaj.org/article/39d3aa3066d64189aaf2033276fee2f52021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921011615https://doaj.org/toc/2531-1379Objective: T-cell prolymphocytic leukemia (T-PLL) is a rare and highly aggressive T cell neoplasm with rapidly progressing clinical course. T-PLL accounts for 2% of mature lymphocytic leukemia in adults. Median overall survival with modern therapy is reported one to three years. Here we report a T-PLL patient with peritoneum involvement and progressive ascite despite anti-CD52 treatment. Case report: A 65-year-old man with diabetes mellitus was admitted to hospital due to fatigue for a few weeks. Laboratory workup revealed that white blood cell count 469 × 103/µl (90% lymphocytes), haemoglobin of 11.4 g/dl, platelets of 104 × 103/µl. Medium sized atypical lymphoid cells with partial chromatin condensation and a visible nucleolus were observed on blood smear. Methodology: On physical examination, palpable inguinal lymph nodes, splenomegaly 3 cm below the rib margin and a palpable lesion on the helix of left ear were noticed. Punch biyopsy of skin lesion was reported as a mature and immature T cell infiltration which are CD3 and CD10 positive and Tdt, CD34, CD20, CD99 negative. Flow cytometric study of peripheral blood sample was revealed that T-Chronic Lymphocytic Leukemia (T-CLL). Results: FMC protocol (fludarabine, mitoxantrone, and cyclophosphamide ) was initiated and followed by intravenous alemtuzumab at a dose of 3 mg on day 1, 10 mg on day 2 and 30 mg on day 3. However after two months of anti-CD52 treatment, his general situation deteriorated and pleural effusion and abdominal distension developed due to massive ascites. Small, mature lymphocytic cell infiltration was shown in ascites fluid on cytological examination. He died after six months of diagnosis. Conclusion: T-PLL is a very aggressive disease with a median survival of less than 1 year. Not all patients diagnosed with T-PLL require treatment immediately.Currently, IV alemtuzumab (anti-CD52) is the accepted best avaliable treatment with very high response rates when given as first-line treatment. However, treatment is notcurative and a minority of T-PLL patients experience long-term disease-free survival.Senem MARALMurat ALBAYRAKHacer Berna OZTURKMerihREIS ARASFatma YILMAZPınar TIGLIOGLUMesut TIGLIOGLUBuğra SAGLAMElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S34-S35 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Senem MARAL Murat ALBAYRAK Hacer Berna OZTURK MerihREIS ARAS Fatma YILMAZ Pınar TIGLIOGLU Mesut TIGLIOGLU Buğra SAGLAM ANTI-CD52 TREATMENT EXPERIENCE IN A T-CELL PROLYMPHOCYTIC LEUKEMIA PATIENT:CASE REPORT
description	Objective: T-cell prolymphocytic leukemia (T-PLL) is a rare and highly aggressive T cell neoplasm with rapidly progressing clinical course. T-PLL accounts for 2% of mature lymphocytic leukemia in adults. Median overall survival with modern therapy is reported one to three years. Here we report a T-PLL patient with peritoneum involvement and progressive ascite despite anti-CD52 treatment. Case report: A 65-year-old man with diabetes mellitus was admitted to hospital due to fatigue for a few weeks. Laboratory workup revealed that white blood cell count 469 × 103/µl (90% lymphocytes), haemoglobin of 11.4 g/dl, platelets of 104 × 103/µl. Medium sized atypical lymphoid cells with partial chromatin condensation and a visible nucleolus were observed on blood smear. Methodology: On physical examination, palpable inguinal lymph nodes, splenomegaly 3 cm below the rib margin and a palpable lesion on the helix of left ear were noticed. Punch biyopsy of skin lesion was reported as a mature and immature T cell infiltration which are CD3 and CD10 positive and Tdt, CD34, CD20, CD99 negative. Flow cytometric study of peripheral blood sample was revealed that T-Chronic Lymphocytic Leukemia (T-CLL). Results: FMC protocol (fludarabine, mitoxantrone, and cyclophosphamide ) was initiated and followed by intravenous alemtuzumab at a dose of 3 mg on day 1, 10 mg on day 2 and 30 mg on day 3. However after two months of anti-CD52 treatment, his general situation deteriorated and pleural effusion and abdominal distension developed due to massive ascites. Small, mature lymphocytic cell infiltration was shown in ascites fluid on cytological examination. He died after six months of diagnosis. Conclusion: T-PLL is a very aggressive disease with a median survival of less than 1 year. Not all patients diagnosed with T-PLL require treatment immediately.Currently, IV alemtuzumab (anti-CD52) is the accepted best avaliable treatment with very high response rates when given as first-line treatment. However, treatment is notcurative and a minority of T-PLL patients experience long-term disease-free survival.
format	article
author	Senem MARAL Murat ALBAYRAK Hacer Berna OZTURK MerihREIS ARAS Fatma YILMAZ Pınar TIGLIOGLU Mesut TIGLIOGLU Buğra SAGLAM
author_facet	Senem MARAL Murat ALBAYRAK Hacer Berna OZTURK MerihREIS ARAS Fatma YILMAZ Pınar TIGLIOGLU Mesut TIGLIOGLU Buğra SAGLAM
author_sort	Senem MARAL
title	ANTI-CD52 TREATMENT EXPERIENCE IN A T-CELL PROLYMPHOCYTIC LEUKEMIA PATIENT:CASE REPORT
title_short	ANTI-CD52 TREATMENT EXPERIENCE IN A T-CELL PROLYMPHOCYTIC LEUKEMIA PATIENT:CASE REPORT
title_full	ANTI-CD52 TREATMENT EXPERIENCE IN A T-CELL PROLYMPHOCYTIC LEUKEMIA PATIENT:CASE REPORT
title_fullStr	ANTI-CD52 TREATMENT EXPERIENCE IN A T-CELL PROLYMPHOCYTIC LEUKEMIA PATIENT:CASE REPORT
title_full_unstemmed	ANTI-CD52 TREATMENT EXPERIENCE IN A T-CELL PROLYMPHOCYTIC LEUKEMIA PATIENT:CASE REPORT
title_sort	anti-cd52 treatment experience in a t-cell prolymphocytic leukemia patient:case report
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/39d3aa3066d64189aaf2033276fee2f5
work_keys_str_mv	AT senemmaral anticd52treatmentexperienceinatcellprolymphocyticleukemiapatientcasereport AT muratalbayrak anticd52treatmentexperienceinatcellprolymphocyticleukemiapatientcasereport AT hacerbernaozturk anticd52treatmentexperienceinatcellprolymphocyticleukemiapatientcasereport AT merihreisaras anticd52treatmentexperienceinatcellprolymphocyticleukemiapatientcasereport AT fatmayilmaz anticd52treatmentexperienceinatcellprolymphocyticleukemiapatientcasereport AT pınartiglioglu anticd52treatmentexperienceinatcellprolymphocyticleukemiapatientcasereport AT mesuttiglioglu anticd52treatmentexperienceinatcellprolymphocyticleukemiapatientcasereport AT bugrasaglam anticd52treatmentexperienceinatcellprolymphocyticleukemiapatientcasereport
_version_	1718440544317734912

ANTI-CD52 TREATMENT EXPERIENCE IN A T-CELL PROLYMPHOCYTIC LEUKEMIA PATIENT:CASE REPORT

Ejemplares similares